Shire PLC  

(Public, LON:SHP)   Watch this stock  
Find more results for SHP
4,869.99
-36.01 (-0.73%)
Jul 28 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 4,818.00 - 4,943.00
52 week 2,707.19 - 5,870.00
Open 4,907.00
Vol / Avg. 2.15M/2.49M
Mkt cap 43.40B*
P/E 28.63
Div/yield 15.32*
EPS 1.70*
Shares 898.56M
Beta     -
Inst. own     -
*GBP
Aug 2, 2016
Q2 2016 Shire PLC Earnings Call - 2:00PM GMT+1 - Add to calendar
Aug 2, 2016
Q2 2016 Shire PLC Earnings Release - 12:00PM GMT+1 - Add to calendar
Jun 9, 2016
Shire PLC at Jefferies Healthcare Conference
Jun 8, 2016
Shire PLC at Goldman Sachs Global Healthcare Conference
May 27, 2016
Shire PLC Ordinary Shareholders Meeting
May 4, 2016
Shire PLC at Deutsche Bank Health Care Conference
  

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin 23.96% 20.88%
Operating margin 31.82% 22.12%
EBITD margin - 44.15%
Return on average assets 8.08% 8.86%
Return on average equity 16.32% 14.47%
Employees 5,548 -
CDP Score - 91 B

Address

5 Riverwalk Citywest Business Campus, Dublin 24
DUBLIN,
Ireland
+353-1-4297700 (Phone)
+353-1-4297701 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance

Description

Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. The Company's products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSEVUXEN/ADUVANZ (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), LIALDA (mesalamine)/MEZAVANT(mesalazine), PENTASA (mesalamine), REPLAGAL (agalsidase alfa), ELAPRASE (idursulfase), VPRIV (velaglucerase alfa), FIRAZYR (icatibant), FOSRENOL (lanthanum carbonate), KALBITOR, CINRYZE C1 esterase inhibitor (human), GATTEX/REVESTIVE, BUMINATE 25% Albumin (Human), BUMINATE 5% Albumin (Human), GLASSIA Alpha1-Proteinase Inhibitor (Human) and ONCASPAR pegaspargase.

Officers and directors

Flemming Ornskov M.D. Chief Executive Officer, Executive Director
Age: 57
Jeffrey Poulton Chief Financial Officer, Director
Age: 47
Ginger Gregory Chief Human Resource Officer
Mark J. Enyedy Interim General Counsel, Head of Corporate Development
Age: 52
Phil J. Vickers Head of Research and Development
Age: 55
Oliver Strawbridge Senior Assistant Company Secretary
Susan Saltzbart Kilsby Non-Executive Chairman of the Board
Age: 57
Olivier Bohuon Non-Executive Director
Age: 56
Gail D. Fosler Non-Executive Director
Age: 68
Sara Mathew Non-Executive Director
Age: 60